Drug
ISIS 304801 clinical trials
Also written ISIS 304801 and Volanesorsen.
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 1
Ionis Pharmaceuticals, Inc. (3) · Akcea Therapeutics (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)
Studies
Open first, then newest update. How each study uses ISIS 304801 is read from its arms, and is right about nine times in ten.
Testing it · 6
- The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia SyndromeCompletedPhase 3Ionis Pharmaceuticals, Inc.NCT02211209Written as Volanesorsen
- The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With HypertriglyceridemiaCompletedPhase 3Ionis Pharmaceuticals, Inc.NCT02300233Written as Volanesorsen
- A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy VolunteersCompletedPhase 1Ionis Pharmaceuticals, Inc.NCT02910635Written as Volanesorsen
- The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial LipodystrophyTerminatedPhase 2/3Akcea TherapeuticsNCT02527343Written as volanesorsen
- The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia SyndromeCompletedPhase 3Akcea TherapeuticsNCT02658175Written as Volanesorsen
- Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label ExtensionCompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT02639286Written as ISIS 304801